We assessed the mRNA expression level of 38 PTPs in 66 newly diagnosed CML patients and analyzed the potential relation with treatment outcome after 9 months of nilotinib medication. The gene discussed is PTS; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.